INDICATIONS
Adjuvant Treatment Of Early Breast Cancer
Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Extended Adjuvant Treatment Of Early Breast Cancer
Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with Femara for a median of 60 months
First And Second-Line Treatment Of Advanced Breast Cancer
Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy
DOSAGE AND ADMINISTRATION
Recommended Dose
The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.
Use In Adjuvant Treatment Of Early Breast Cancer
In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. In both the adjuvant study and the post approval adjuvant study, median treatment duration was 5 years. Treatment should be discontinued at relapse .
Use In Extended Adjuvant Treatment Of Early Breast Cancer
In the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration for Femara was 60 months. Seventy-one (71%) percent of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse .
Use In First And Second-Line Treatment Of Advanced Breast Cancer
In patients with advanced disease, treatment with Femara should continue until tumor progression is evident.
Use In Hepatic Impairment
No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see WARNINGS AND PRECAUTIONS]. The recommended dose of Femara for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.
Use In Renal Impairment
No dosage adjustment is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min
FAQ
1. Can I get a free sample
Yes, but you have to pay the courier fee.
2. How to pay
We accept payments in the form of , MoneyGram, Bitcoin, etc.
3. What should I do if we don’t ship after payment
We are a formal company certified by LOOKCHEM Integrity, you can provide proof of payment to LOOKCHEM complaints.
4. How long after the payment can be shipped
We have stocked products that are shipped within 24 hours. If you need to customize the product, we will negotiate the delivery cycle.
5. How is the safety of transportation
We will choose the safest delivery method to ensure customs clearance and safety during transportation.
6. What kind of company is THETA BIO
In 2009, Dr Zhang Lin from Johns Hopkins University founded the theta Biological Laboratory. He is committed to the study of protein assimilation preparations.
In 2013,Dr Zhang Lin returned to China to work in MSD China, and continued to work on biopharmaceutical research and development.
In 2018,Dr Zhang Lin founded shaoyang Theta Biological Thechnology Co.,Ltd.
Business Scope:
Pharmaceutical intermediate
Biotechology development
Fine organic chemistry
Biopharmaceutical